CorMedix (CRMD) shares were up over 20% in recent trading on Tuesday after its Q1 net income and revenue surpassed analysts' consensus.
The company reported Q1 results swung to net income Tuesday of $0.30 per diluted share, from a loss of $0.25 a year earlier.
Analysts polled by FactSet expected EPS of $0.26.
Revenue for the quarter ended March 31 was $39.1 million.
Analysts surveyed by FactSet expected $36.9 million.
CorMedix expects to be at the high-end of the previously announced first half net sales guidance of $62 million to $70 million.
As of March 31, the company said it had $77.5 million in cash and/or cash equivalents on hand, and expected it could fund operations for at least 12 months from the issuance of its quarterly report on From 10-Q.
Price: 10.92, Change: +1.89, Percent Change: +20.87
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。